

Chronische postoperatieve en traumawonden

“acute chronische wonden”



APRIL23

Harm Jaap Smit

Kennis maken

- Moleculair bioloog / BioMedServ BV
- Coloplast (1996), TheWoundCareCompany, Taureon.
- Docent wondverpleegkunde & wondconsulent Erasmus
- Expert team Wondplatform
- Editorial board: Journal of Wound Care, Wound Masterclass
- Disclosure:
 - advisory board: Utermohlen, Coloplast, Debx, Innova,
 - aandelen: BioMedServ BV, Icap holding BV
- Lastige vragen

Hoe dan?

The effect of postoperative closed incision negative pressure therapy on the incidence of donor site wound dehiscence in breast reconstruction patients: DEhiscence PREvention Study (DEPRES), pilot randomized controlled trial

E. Muller-Sloof^{a,*}, H.E.W. de Laat^a, S.L.M. Hummelink^a, J.W.B. Peters^b, D.J.O. Ulrich^a

^a Department of Plastic and Reconstructive Surgery, Radboud University Medical Center, P/O Box 9101, 6500 HB, Nijmegen, The Netherlands

^b HAN University Applied Sciences, Department Master Advanced Nursing Practice, Groenewoudseweg 1, 6524 TM, Nijmegen, The Netherlands

1. Introduction

Wound dehiscence is the rupturing or splitting apart of the margins of a clean closed incision which may be partial or complete and may be superficial or may involve the deeper tissue layers [1–5]. Wound dehiscence is a serious postoperative complication with high morbidity and high mortality up to 50% [5–9] and contributes to delays in the recovery process, repeat operations, prolonged hospital stays, high care costs, and reduced ability to self-care [9].

Autologous deep inferior epigastric perforator (DIEP) flap breast reconstructions are increasingly popular operations in breast

From the Department of Plastic and Reconstructive Surgery and Radboud Institute for Health Sciences Scientific Center


contribute to an infection. As discussed in the beginning of this article, presence of an SSI leads to a significant risk of development of both a burst abdomen and incisional hernia. Surgical site infections represent 14% of all nosocomial infections and 5% of all surgical complications (46). SSI after midline laparotomy reach up to 16%, prolonging hospital stay,

cancer patients who have undergone a therapeutic or prophylactic mastectomy.¹ However, abdominal donor-site wound dehiscence, which is a serious postoperative complication,^{2,3} occurs in 7.4 to 33 percent of cases.⁴⁻⁶


1. Muller-Sloof E, de Laat E, Kenc O, Kumas A, Vermeulen H, Hummelink S, et al. Closed-Incision Negative-Pressure Therapy Reduces Donor-Site Surgical Wound Dehiscence in DIEP Flap Breast Reconstructions: A Randomized Clinical Trial. *Plast Reconstr Surg.* 2022;150:385-475.
2. Muller-Sloof E, de Laat HEW, Hummelink SLM, Peters JWB, Ulrich DJO. The effect of postoperative closed incision negative pressure therapy on the incidence of donor site wound dehiscence in breast reconstruction patients: DEhiscence PREvention Study (DEPRES), pilot randomized controlled trial. *Journal of Tissue Viability.*
3. Theodorou A, Banysch M, Gok H, Deerenberg EB, Kalff JC, von Websky MW. Don't fear the (small) bite: A narrative review of the rationale and misconceptions surrounding closure of abdominal wall incisions. *Front Surg.* 2022;9:1002558 2018:0-1.

Wat gebeurt er in Nederland

diagnose huisarts




diagnose gespecialiseerde thuiszorg




- overig
- trauma / postop
- been ulcera
- decubitus
- diab voet


Sluiting in de tijd




De samenstelling van de patiëntengroep veranderd naarmate de wonden langer open zijn.




Sluitingssnelheid per level



7 DAGEN



1JAAR




- Post traumatic/surgical wound
- Pressure ulcer
- Diabetic foot ulcer
- Leg ulcer
- Burns
- Malignant oncologic

	7_days	365_days	%
Post traumatic/surgical wound	972	29	3,0%
Pressure ulcer	466	14	3,0%
Diabetic foot ulcer	407	36	8,8%
Leg ulcer	397	20	5,0%
Burns	74	0	0,0%
Malignant oncologic	15	2	13,3%


Diagnose

- Arterieel ulcus
- Chirurgische Wond
- Erysipelas
- Oedeem
- Vasculitis ulcus
- Blaar
- Decubitus ulcus
- Gemengd arterieel-veneus ulcus
- Overig
- Veneus Ulcus
- Brandwond
- Diabetisch ulcus
- Maligniteit
- Trauma ulcus


Totaal



1+ Jaar



		365_days	
Post traumatic/surgical wound	37%	22%	



Indeling wonden kan veel eenvoudiger!

Er zijn maar **twee** soorten en **twee** uitzonderingen

Je hebt een wond omdat:

1. Omdat je iets overkomt (acuut).
2. Omdat je een probleem hebt (hopelijk niet chronisch).

Uitzonderingen:

1. De wond is groot en zit op een verkeerde plek.
2. Door de wond ontdek je dat je een probleem hebt.



Postoperatieve problemen kennen een aantal oorzaken

Patient related	Surgeon/technique related	Material related
Obesity	Incision site	Suture material
Smoking	Incision technique	
Diabetes	Suture technique	
Collagen deficiency	Wound contamination	
Immunosuppression	Postoperative Management	
Nutritional deficiency	Skin closure	
Clinical condition (sepsis, shock)	NPWT application	

Technique related factors

1. Continuous vs. interrupted suture
2. Suture length to wound length ratio
3. Bite size
4. Mass closure vs. aponeurosis only
5. Tension


Material related factors

- i. Needle size
- ii. Absorbable vs non Absorbable
- iii. Antibacterial coated/non coated
- iiii. Monofilament vs. multifilament


Theodorou A, Banysh M, Gok H, Deerenberg EB, Kalff JC, von Websky MW. Don't fear the (small) bite: A narrative review of the rationale and misconceptions surrounding closure of abdominal wall incisions. *Front Surg.* 2022;9:1002558.

Badkuipmodel wondbehandeling

(water=schade)



Patient work up

0	 	NAW (postcode!), geslacht, leeftijd, locatie, duur, T½, Altis (I)		Aarde
1	 	SCEGS , gezondheidsvaardigheden/mogelijkheden, partner/mantelzorg, SNAQ-voeding, comorbiditeit, Altis (II), lab (glucose, HbA1c, nierfunctie, HB, cholesterol, CRP en leucocyten), medicatie (Start/stopp, corticosteroiden, biologicals), fitheid/conditie (beweging). (driving the bus)		Samenleving
2	 	Debridement, TIME, compartimenten, kweek.		Sociale omgeving
3	 	Cardiovasculair, vaatstatus, nierfunctie, endocrinologieglucose regeling, neuropathie, mobiliteit, oncologie, huidaandoeningen,...		Patiënt
4	 	Complement, inflammatie, fasen wondgenezing, MMP's/TIMP's, familiere toets.		Orgaanstelsels
				Organen
				Weefsels
				Cellen
				Organelen
				Moleculen
				Atomen



EINDE